mTOR/STAT3 신호억제제 처리된 면역조절능을 갖는 간엽줄기세포 및 이를 포함하는 면역질환의 예방 또는 치료용 세포치료제 조성물
    21.
    发明授权
    mTOR/STAT3 신호억제제 처리된 면역조절능을 갖는 간엽줄기세포 및 이를 포함하는 면역질환의 예방 또는 치료용 세포치료제 조성물 有权
    的mTOR / STAT3具有用于预防或治疗,其包括相同的免疫疾病的免疫调节手柄功能间充质干细胞和细胞治疗组合物信号抑制剂

    公开(公告)号:KR101723265B1

    公开(公告)日:2017-04-04

    申请号:KR1020140104575

    申请日:2014-08-12

    Abstract: 본발명은면역조절능을갖는간엽줄기세포및 이의제조방법에관한것으로, 보다구체적으로라파마이신이처리된면역조절능을갖는간엽줄기세포에있어서; CCR1, CCR2, CCR3, CCR4, CCR7, CCR9 및 CXCR4로이루어진군으로부터선택되는어느하나이상의세포표면인자가발현되는간엽줄기세포, 상기간엽줄기세포를포함하는면역질환의예방또는치료용세포치료제조성물및 면역조절능을갖는간엽줄기세포의제조방법에관한것이다. 본발명에따른라파마이신(rapamycin)이처리된면역조절능을갖는간엽줄기세포는면역조절능을갖는인자인 IDO, TGF-beta 및 IL-10의발현이증가되어있고, mTOR의신호전달인자인 Phospho-mTOR, Rictor 및 Ractor의발현은감소되어있으며, 자가포식유도인자인 Beclin1, ATG5, ATG7, LC3I 또는 LCII의발현이상기세포내에서증가되어있는세포로서, 이세포를면역질환개체에세포치료제로사용하는경우, 효과적으로면역질환을치료할수 있는효과가있다.

    Abstract translation: 本发明涉及间充质干细胞与,更具体地,雷帕霉素治疗的免疫调节功能涉及间充质干细胞和免疫调节具有功能的方法; CCR1,CCR2,CCR3,CCR4,CCR7,CCR9和被表达间充质干细胞,包括间充质干细胞治疗组合物的免疫疾病的预防和治疗以及选自CXCR4的组中选择的细胞表面标记物的任何一种或多种 生产具有免疫调节能力的间充质干细胞的方法。 用雷帕霉素(雷帕霉素)的间充质处理免疫调节作用在根据本发明的干细胞是具有免疫调节功能的IDO,TGF-β和IL-10 uibal的因子和在信号转导因子的磷酸增加了弦,mTOR的 -mTOR,Rictor的和Ractor的表达降低,并且,作为Beclin1基因,ATG5,ATG7,细胞的自捕食诱导剂,其是在上述干细胞或LC3I LCII的表达增加,在自身免疫性疾病中的细胞治疗中使用的细胞对象 它可以有效治疗免疫疾病。

    이식 후 면역 상태를 모니터링 하는 키트 및 이를 이용한 면역 상태의 모니터링 방법
    22.
    发明公开
    이식 후 면역 상태를 모니터링 하는 키트 및 이를 이용한 면역 상태의 모니터링 방법 有权
    监测植入后的免疫学试剂和使用其监测免疫反应的方法

    公开(公告)号:KR1020130126554A

    公开(公告)日:2013-11-20

    申请号:KR1020130053814

    申请日:2013-05-13

    Abstract: The present invention relates to a monitoring kit for an immune status after transplantation, and more particularly, a monitoring kit for the immune status after the transplantation, containing materials for measuring Th17 cells, Treg cells, Th1 cells, CD8EM(CD8 effect memory) IFN-γ-positive cells, and CD8CM(CD8 central memory) IFN-γ-positive cells, and a monitoring method for the immune status of the individual receiving the transplantation including a step of measuring the cell number of Th17 cells, Treg cells, Th1 cells, CD8EM IFN-γ-positive cells, and CD8CM IFN-γ-positive cells against the peripheral blood of an object receiving the transplantation, and a step for calculating each cell number ratio of Treg cells, Th1 cells, CD8EM IFN-γ-positive cells, and CD8CM IFN-γ-positive cells against the number of Th17 cells by dividing the measured values of cell numbers of Treg cells, Th1 cells, CD8EM IFN-γ-positive cells, and CD8CM IFN-γ-positive cells with the measured value of the cell number of Th17 cells. The monitoring method and kit for the immune status of the individual receiving the transplantation provided by the present invention are capable of determining the immune status with ease and accuracy, thereby reducing the excessive use of an immunosuppressant prescribed after transplantation and managing the immune status of each patient. [Reference numerals] (AA,EE,II,MM,QQ,UU) Normally take CNI (100% taking);(BB,DD,FF,HH,JJ,LL,NN,PP,RR,TT,VV,XX) Reduce CNI by 25% (75% taking);(CC,GG,KK,OO,SS,WW) Reduce CNI 50% (50% taking)

    Abstract translation: 本发明涉及用于移植后免疫状态的监测试剂盒,更具体地,涉及用于移植后免疫状态的监测试剂盒,其包含用于测量Th17细胞,Treg细胞,Th1细胞,CD8EM(CD8效应记忆)IFN - γ阳性细胞和CD8CM(CD8中枢记忆)IFN-γ阳性细胞,以及接受移植的个体的免疫状态的监测方法,包括测量Th17细胞,Treg细胞的细胞数的步骤 ,Th1细胞,CD8EM IFN-γ阳性细胞和CD8CM IFN-γ阳性细胞对抗接受移植的对象的外周血,以及计算Treg细胞,Th1细胞,CD8EM的每个细胞数比例的步骤 通过将Treg细胞,Th1细胞,CD8EM IFN-γ阳性细胞和CD8CM IFN的细胞数量的测量值除以相对于Th17细胞数量的IFN-γ阳性细胞和CD8CM IFN-γ阳性细胞 - &伽马; -posi T细胞与Th17细胞的细胞数量的测量值。 本发明提供的接受移植的个体的免疫状态的监测方法和试剂盒能够容易且准确地测定免疫状态,从而减少移植后规定的免疫抑制剂的过度使用,并且管理每种免疫抑制剂的免疫状态 患者。 (AA,EE,II,MM,QQ,UU)通常采用CNI(100%服用);(BB,DD,FF,HH,JJ,LL,NN,PP,RR,TT,VV,XX )将CNI降低25%(75%服用);(CC,GG,KK,OO,SS,WW)减少CNI 50%(50%服用)

Patent Agency Ranking